Compare VINP & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VINP | PCRX |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.6M | 1.0B |
| IPO Year | 2020 | 2010 |
| Metric | VINP | PCRX |
|---|---|---|
| Price | $10.25 | $23.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $14.00 | ★ $37.60 |
| AVG Volume (30 Days) | 73.2K | ★ 740.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $23.80 | $9.77 |
| Revenue Next Year | $13.97 | $9.71 |
| P/E Ratio | ★ $24.41 | $147.31 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $8.66 | $18.80 |
| 52 Week High | $13.61 | $27.99 |
| Indicator | VINP | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 23.09 | 55.05 |
| Support Level | $9.25 | $23.10 |
| Resistance Level | $10.87 | $23.82 |
| Average True Range (ATR) | 0.60 | 1.06 |
| MACD | -0.18 | 0.08 |
| Stochastic Oscillator | 0.19 | 77.96 |
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.